Simplified Chinese
scroll down
27
2017-11
Our company has passed the quality assurance system inspection conducted by the Drug Administration.
Recently, inspection teams from the Beijing Municipal Administration for Market Regulation and the Daxing District Administration for Market Regulation visited our company to conduct routine follow-up inspections. The company’s General Manager, Zheng Haifa, Executive Deputy General Manager, Liu Jiankai, Quality Director, Li Xiangqun, and other relevant personnel accompanied the team throughout the process. Using methods such as interviews, on-site visits, document reviews, and record examinations, the inspection team conducted a comprehensive assessment of the operation of the company’s quality assurance system.
27
2017-11
Recently, Minhai, as one of the member companies of the Developing Countries Vaccine Manufacturers Network (DCVMN), was invited to attend the 18th Annual Meeting of the DCVMN, held in Seoul, South Korea. The conference brought together representatives from the World Health Organization (WHO), UNICEF, the Global Alliance for Vaccines and Immunization (GAVI), the Bill & Melinda Gates Foundation, as well as more than 50 member companies.
10
2017-10
On the morning of September 28, the evaluation and defense meeting for postdoctoral fellows Xu Yingzhi, who is scheduled to leave the station, and Liu Jiandong and Li Kelei, who are joining the station, was held in the company’s First Conference Room. The company invited Academician Rao Zihe of the Chinese Academy of Sciences, Researcher Liu Ruitian from the Institute of Process Engineering of the Chinese Academy of Sciences, Professor Zhang Jingren of the Center for Infectious Disease Research at the School of Medicine, Tsinghua University, Researcher Liang Zhenglun from the National Institute for Food and Drug Control, as well as Researcher Zheng Haifa, head of the company’s postdoctoral workstation, and Professor Liu Jiankai to form the evaluation panel, with Researcher Zheng Haifa serving as the panel chair. Professor Liu Jiankai presided over the meeting.
26
2017-09
At the invitation of Cuba’s Biotechnology and Pharmaceutical Group (BioCubaFarma), Du Weimin, Chairman of Kangtai Biological; Zheng Haifa, Deputy General Manager; and Zhang Qian, Head of International Cooperation, attended the Ninth Closed‑Door Meeting of the China–Cuba Joint Working Group on Biotechnology, held in Guangzhou on July 3–4, 2017. Participants included representatives from Cuba’s Biotechnology and Pharmaceutical Group, the Cuban Center for Genetic Engineering and Biotechnology, the Cuban Center for Molecular Immunology, the Cuban Institute of Ophthalmology and the National Center for Scientific Research, as well as the Cuban Embassy in China, the Cuban National Center for Medicines and Medical Devices, and China’s National Development and Reform Commission and Ministry of Foreign Affairs.
10
2017-08
I. Project Name: R&D and Production Building (R&D and Production Building Construction Project) II. Project Overview: This project is located at No. 35 Simiao Road, Biomedical Industry Base, Daxing District, Beijing. The building measures 112.9 m in length and 54.7 m in width, with one basement level and a total floor area of 6,299.39 m². Above ground, there are three floors totaling 21,042.12 m², for a combined gross floor area of 27,341.51 m². The basement has a floor-to-floor height of 5.2 m, the above-ground floors are 7.6 m high, and the mezzanine level stands at 3.8 m. The overall building height is 24 m. The structure is a reinforced concrete frame system. III. Scope of Tender: The scope of this tender covers the R&D and Production Building (R&D and Production Building Construction).
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%